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As the AIDS pandemic has continued, our understanding of the events that occur during the entry 12 
and infection of conventional, susceptible cells has increased dramatically, leading to the 13 
development of control therapies for HIV infected individuals.  However, an ongoing hole in our 14 
understanding is how HIV crosses the mucosal barriers to gain access to permissive cells, despite 15 
how important this information would be in developing successful vaccines and other preventative 16 
measures such as topical anti-HIV microbicides.  In particular, our knowledge of the role that 17 
epithelial cells of the mucosal surfaces play in infection – both during early phases and throughout 18 
the life of an infected individual, is currently hazy at best. However, several studies in recent years 19 
suggest that HIV can bind to and traverse these mucosal epithelial cells, providing a reservoir of 20 
infection that can subsequently infect underlying permissive cells. Despite this interaction with 21 
epithelial cells, evidence suggests HIV-1 does not productively infect these cells, although they are 22 
capable of transferring surface-bound and transcytosed virus to other, permissive cells. Further, 23 
there appear to be key differences between adult and infant epithelial cells in the degree to which 24 
HIV can transcytose and infect the epithelium.  Thus, it is clear that, whilst not primary targets for 25 
infection and virus replication, epithelial cells play an important role in the infection cycle and 26 
improving our understanding of their interactions with HIV could potentially provide key insights 27 




Despite a reduction in the number of articles about the HIV epidemic in the Western press over the 30 
last two decades, HIV infection is a major ongoing issue in global health.  Recent epidemiology 31 
figures indicate that at the end of 2014 there were approximately 37 million people living with HIV. 32 
During 2014, approximately 2 million fresh cases of infection were reported, whilst around 1.2 33 
million people died of HIV/AIDS related illness (UNAIDS, 2015). This, however, could be just the tip of 34 
the iceberg. Estimates suggest that only about 50% of cases are reported, implying that the true 35 
figures for infection are much higher. Although the introduction of HAART therapy has been a bright 36 
spot in the landscape of the HIV Pandemic (along with other measures, the era of HAART therapy 37 
has seen a 42% drop in annual mortality in 2014 since its peak in 2004), we are currently still no 38 
closer to developing effective therapies such as vaccines and topical anti-HIV microbicides that could 39 
be used to prevent infection in the first place. A key step in the fight to develop these therapeutics is 40 
improving our currently poor understanding of HIV infection at mucosal surfaces. 41 
The primary infection route for HIV-1 is across mucosal surfaces such as the gastrointestinal and 42 
genital tracts (Hladik & McElrath, 2008), with exposure occurring during events such as sexual 43 
activity and breast-feeding. Currently, the majority of new infections occur as a result of 44 
heterosexual transmission in adults, with HIV-1 having been isolated from both seminal fluid and 45 
cervicovaginal secretions (Coombs et al., 1998, Dulioust et al., 1998, Goulston et al., 1998). In 46 
infants, however, infection by HIV-1 typically occurs as a result of breast-feeding, with the oral and 47 
oropharyngeal tissues representing the initial exposure sites. Effective transmission across genital 48 
mucosal surfaces (in particular, the vagina, ecto-and endocervix and uterus) is assisted by the 49 
presence of HIV-1 target cells within these surfaces, such as dendritic cells, macrophages and 50 
lymphocytes (Yeaman et al., 1998, Ballweber et al., 2011, Shen et al., 2011, Kaldensjo et al., 2011, 51 
Hladik et al., 2007, Miller & Shattock, 2003, Bhoopat et al., 2001, Hu et al., 2004, Maher et al., 2005). 52 
Indeed, it has been established that dendritic cells can sample mucosal surfaces such as the gut 53 
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directly, without needing antigens to be transported through the epithelial layer (Niess et al., 2005). 54 
However, a subset of dendritic cells, the Langerhans cells, has been shown to have an anti-HIV 55 
function, mediated by the Langerin surface receptor (de Witte et al., 2007), and these cells are 56 
known to be poresent in oral mucosa (Hussain & Lehner, 1995). The key role of both dendritic and 57 
Langerhans cells in HIV infection is extensively reviewed elsewhere (van den Berg & Geijtenbeek, 58 
2013). Despite the apparent ease with which HIV crosses the genital and rectal mucosa, transmission 59 
across the oral mucosa is thought to be rare (Milman & Sharma, 1994, Janoff & Smith, 2001, 60 
Wilkinson & Cunningham, 2006, Cohen et al., 2000, Rothenberg et al., 1998, Jotwani et al., 2004), 61 
with several mechanisms (such as neutralizing antibodies, innate anti-HIV salivary factors, presence 62 
of Langerhans cells and the epithelium) proposed to explain this phenomenon (Challacombe & 63 
Naglik, 2006, Herzberg et al., 2006, Kazmi et al., 2006, Malamud & Wahl, 2010, Weinberg et al., 64 
2011). Despite this, oral transmission can occur.  For example, SIV transmission across non-65 
traumatised oral epithelia, resulting in dissemination and systemic infection in primates has been 66 
reported in several studies (Baba et al., 1996, Herz et al., 2002, Joag et al., 1997, Milush et al., 2004).  67 
As a result, the epithelium may represent either a physical barrier against direct infection or a 68 
potential reservoir to aid infection. The importance of determining which of these is prevalent is of 69 
particular importance, given the potential for viral transference in nursing infants or during oro-70 
genital contact in adults. 71 
Initial contact with oral mucosa 72 
The initial contact between the host and HIV-1 in the oral cavity occurs between virus and the oral 73 
and oropharyngeal mucosal tissues (Herzberg et al., 2006). However, given the variety of cell types, 74 
along with the preponderance of epithelial cells in these tissues, neither the primary infected cell 75 
type, nor the initial site of infection has as yet been identified. It has become evident, however, that 76 
upon exposure of these sites to the virus, an anti-HIV response is generated. For example, after 77 
unprotected oro-genital contact with an HIV+ partner, uninfected men have been shown to mount a 78 
5 
 
salivary IgA1 response that neutralises the HIV-1 virions (Hasselrot et al., 2009), thus demonstrating 79 
that far from remaining ignorant of the presence of the virion, these surfaces are capable of 80 
recognising and responding to HIV-1.  What is unclear is where the response is initiated.  Are these 81 
responses a result of viral interaction with and infection of resident infectable immune cells such as 82 
langerhans dendritic cells or macrophages or, more controversially, are they instigated through 83 
recognition of viral particles by the epithelial cells that make up the majority of these surfaces?  On 84 
the face of it, this seems like an easy answer - epithelial cells are not known for their expression of 85 
the canonical receptors for HIV - namely CD4, CCR5 and CXCR4, so they should not be infected or 86 
interact directly with the virus. Further, extensive research over the years has identified CD4+ T cells 87 
and macrophages, along with dendritic cells, as being the key target cells of the HIV virus.  However, 88 
over the last decade, there has been a small but persistent number of studies from different groups 89 
suggesting that HIV can interact, associate with or even infect epithelial cells (Vacharaksa et al., 90 
2008, Kohli et al., 2014, Rodriguez-Inigo et al., 2005, Liu et al., 2003, Moore et al., 2002, Moore et al., 91 
2003). These studies suggests that oral epithelial cells themselves may play a key role in the initial 92 
contact events in the oral cavity, possibly being the initial point of contact. However, whether the 93 
epithelial cells that make up the oral mucosa can serve as a reservoir for HIV-1 virions during initial 94 
or subsequent infection events, or even if they can function as a seat of infection remains uncertain 95 
(Richman et al., 2009). The importance of the oral mucosa in HIV infection, however, cannot be 96 
ignored. Whilst anti-HIV immune responses are generated, augmentation of these responses with 97 
topical anti-HIV agents (Li et al., 2009) strongly suggests that infection and evasion of immune 98 
responses at the oral mucosae represents a potential route of infection.  99 
Epithelial cells - infected or bound? 100 
Inherent to the question of whether oral (or other) epithelial cells can be infected by HIV-1, is 101 
whether they possess the correct, canonical HIV receptors – CD4 and CXCR4 or CCR5. The target cells 102 
of an HIV-1 infection (T cells, dendritic cells and macrophages) all express CD4 and either or both of 103 
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the chemokine co-receptors, CXCR4 or CCR5. The events during infection of these cells have been 104 
the source of much research and has now been fairly well characterised (Pierson & Doms, 2003). 105 
Initial contact between the viral envelope protein gp120 and host cell CD4 leads to a conformational 106 
change in gp120 followed by further interaction with one or other of the fusion co-receptors, CCR5 107 
or CXCR4. This leads to gp41-mediated fusion of the viral membrane with the host cell membrane, 108 
allowing entry into the cell. Once inside the cell, the HIV-1 RNA genome is reverse transcribed into 109 
DNA and integrated into the host cell genome.  Thus, it would appear that a central requirement in 110 
the infection of a cell is the expression of CD4 and either or both of CCR5 and CXCR4.  Studies by 111 
several groups have clearly demonstrated that, unlike classical HIV-infectable cells (T cells etc), 112 
epithelial cells do not express CD4 (Liu et al., 2003, Kumar et al., 2006, Quinones-Mateu et al., 2003, 113 
Vacharaksa et al., 2008, Kohli et al., 2014, Walsh et al., 1990), whilst levels of CXCR4 and CCR5 are 114 
either very low or undetectable (Kohli et al., 2014, Liu et al., 2013, Vacharaksa et al., 2008, Cutler & 115 
Jotwani, 2006, Giacaman et al., 2008, Berlier et al., 2005, Bobardt et al., 2007, Dezzutti et al., 2001).  116 
Given this apparent lack of HIV-1 binding cellular receptors, the question is how do HIV-1 virions 117 
bind to epithelial cells? The answer to this question is via the use of alternative HIV-associative 118 
receptors. Over the course of the history of HIV-1 research, several different groups have 119 
demonstrated that in addition to the ‘canonical’ receptors CD4 and CCR5/CXCR4, HIV-1 can also bind 120 
to a selection of other cell surface receptors or moieties, utilising substitute mechanisms of binding 121 
and cellular entry (Table 1).  For example, the viral envelope protein gp160 (gp120 and gp41) binds 122 
to, among others, DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-123 
integrin) (Geijtenbeek et al., 2000, van Kooyk & Geijtenbeek, 2003), GalCer (the glycosphingolipid 124 
galactosylceramide) (Alfsen & Bomsel, 2002, Delezay et al., 1997, Harouse et al., 1991) and heparan 125 
sulphate glycans (HSPGs) including the syndecan family receptors (Bobardt et al., 2003, Wu et al., 126 
2003).  Each of these receptors has been shown to play a role in either simply binding the virus and 127 
'passing it on' to target cells (trans-infection) or, in some cases, enhance direct infection of the 128 
binding cell (cis-infection) by an active process as well (e.g. D-SIGN).  Most notable of these is the C-129 
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type lectin DC-SIGN.  Work investigating the interactions of this lectin with HIV-1 gp120 have 130 
indicated that as well as enhancing infection by increasing the concentration of virus on the cellular 131 
surface, it also increases the affinity of gp120 for CD4 (Hijazi et al., 2011). Both GalCer (Magerus-132 
Chatinet et al., 2007) and HPSGs (Jiang et al., 2015) have also been shown to play a role in trans-133 
infection. 134 
These ‘non-canonical’ receptor moieties are expressed on a wider range of cell types than CD4 and 135 
the chemokine co-receptors.  Both GalCer and HSPGs in particular have been shown to be 136 
abundantly expressed in oral epithelial cells, although DC-SIGN is not (Kohli et al., 2014).  This 137 
expression on the epithelial cell component has been proposed as a mechanism promoting the 138 
binding and transfer of HIV-1 virions across both the oral and vaginal epithelial layers thus 139 
improving/aiding initial infection events (Bobardt et al., 2007, Dezzutti et al., 2001, Weinberg et al., 140 
2011, Wu et al., 2003, Yeaman et al., 1998). Given that these interaction processes between non-141 
canonical receptors and HIV-1 are regarded as being co-receptor independent (CXCR4/CCR5), it is, 142 
therefore, somewhat of a surprise that the R5-tropic HIV-1 viruses (those that utilise CCR5 as a co-143 
receptor) appear to be preferentially transmitted across mucosal surfaces (Margolis & Shattock, 144 
2006). 145 
Although there is currently no evidence to indicate that any of these non-canonical receptors can 146 
directly initiate cis-infection of an epithelial cell in a CD4+/CCR5/CXCR4 independent fashion, there 147 
have been studies published that suggest that HIV-1 is capable of infecting and integrating into oral 148 
(Vacharaksa et al., 2008) and genitourinary tract (Hladik et al., 2007) epithelial cells, although in both 149 
cases, this infection was non-productive - i.e. does not result in the production of viral transcripts or 150 
progeny virions.  However, in a more recent study, we demonstrated using a variety of techniques 151 
that whilst both X4- and R5-tropic HIV-1 could bind to oral and vaginal epithelial cells, they were 152 
unable to infect - productively or unproductively (Kohli et al., 2014).  When analysed, virus treated 153 
cells showed not only showed no infective virion production when the virions were pre-treated with 154 
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DNAse to remove any nucleic acid contamination. They also demonstrated no proviral integration, 155 
spliced viral mRNA or de novo synthesis of viral proteins.  The absence of all these indicators of viral 156 
infection and production indicate that although oral and vaginal epithelial cells have a variety of non-157 
canonical HIV receptors on their surface, they appear to be non-permissive to viral infection by the 158 
HIV-1 virus.  It is notable that this non-permissivity to infection by HIV-1 is not down to an inherent 159 
inability of HIV-1 to replicate in epithelial cells.  We found that if a VSV-G pseudotyped  gfp 160 
containing HIV-1 virus (guaranteeing entry via the endocytic pathway) was used to infect epithelial 161 
cells, then normal proviral integration could occur, with infected cells expressing GFP at similar levels 162 
to a permissive cell line. Together with the existence of reporter 'permissive' cell lines that express 163 
CD4, CCR5 and/or CXCR4, such as the TZM-bl line, that are based on epithelial cells, this data 164 
suggests that if the HIV-1 virion can gain entry to oral epithelial cells in a receptor-independent or 165 
other non-conventional mechanisms (such as endocytosis), then this could potentially lead to the 166 
production of infectious virions. Thus, it is possible that when conditions arise in vivo that facilitate 167 
bypassing receptor-mediated entry (e.g. during inflammation events such as gingivitis when cells are 168 
damaged, or by 'piggy backing' on another microbe), epithelial cells in the epithelium could support 169 
productive HIV-1 infections, potentially by harbouring infectious HIV-1 that is then trans-infected to 170 
incoming permissive immune cells (Giavedoni et al., 2013). 171 
 Despite the inability of HIV-1 to successfully infect epithelial cells, however, we like several other 172 
studies found that HIV virions can be bound by epithelial cells, as indicated by the presence of both 173 
gp120 and p24 on infected epithelial cells (determined by flow cytometry and immunoblotting), and 174 
the presence of HIV-1 RNA genome(determined by PCR on RNA isolated from infected cells). 175 
Interestingly, there are difference in the amount of virus bound by epithelial cells from different 176 
locations, with the oropharyngeal FaDu epithelial cell line binding more than either a buccal or 177 
vulvovaginal cell line. The binding (likely through non-canonical receptors) also proved to be trypsin-178 
sensitive, particularly for the R5 trpoic virus (Kohli et al., 2014), suggesting a degree of protein 179 
involvement. Thus, from our study and others, it appears that HIV-1 does indeed bind to epithelial 180 
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cells, although there are differences between cells from different locations.  These differences likely 181 
reflect differences in the expression of the different non-canonical receptors on their surfaces, and 182 
may well change with the age and infection status of an individual, as well as with any drug regimen 183 
the individual is on.  184 
Epithelial cell transfer of HIV-1 185 
Given that HIV-1 can demonstrably bind to epithelial cells, albeit without any accompanying cis-186 
infection, the question arises whether epithelial cells can act as a reservoir in some way for the virus. 187 
The hypothesis would be that surface-bound HIV can be transferred from epithelial cells to other, 188 
susceptible cells, such as dendritic cells, macrophages and T cells integrated in or underlying the 189 
epithelial layer. Although there is a study which was unable to demonstrate successful transfer of 190 
infectious HIV-1 to permissive PBMCs (peripheral blood mononuclear cells) (Berlier et al., 2005), 191 
there are several studies that have produced evidence to support the hypothesis (Yeaman et al., 192 
1998, Ballweber et al., 2011, Shen et al., 2011, Hladik et al., 2007, Khanna et al., 2002, Miller & 193 
Shattock, 2003, Dezzutti et al., 2001, Spira et al., 1996, Hu et al., 2000). With this in mind, we tested 194 
whether epithelial cell-bound HIV could be successfully transferred to a reporter cell line using an 195 
overlay system, and demonstrated that both R5 and X4-tropic virus were capable of retaining 196 
infectivity and being transferred to susceptible cells after being bound by epithelial cells (Kohli et al., 197 
2014). Others have also shown HIV binding activity for oral cells (Liu et al., 2003, Vacharaksa et al., 198 
2008, Wu et al., 2003, Mondor et al., 1998, Roderiquez et al., 1995), which supports the hypothesis 199 
that oral epithelial cells can bind HIV-1 and transfer it to other cells, acting as a 'sump' or reservoir 200 
for the virus - whether it has been produced locally or has come from an external source. What is 201 
not clear at this time is the receptors responsible for this binding. It is clear from studying the effects 202 
of trypsin treatment on the levels of binding that there is some protein interaction involved. 203 
Likewise, studies examining the effects of heparin or heparin sulfate (blocking binding through 204 
HSPGs) indicate that these treatments can also reduce viral attachment (Bobardt et al., 2003, Wu et 205 
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al., 2003, Mondor et al., 1998, Roderiquez et al., 1995). However, there is no current definitive proof 206 
for one specific moiety on either side being key.  The likelihood is that there are a range of 207 
receptor/ligand interactions on both virion and host epithelial cell that all play differing roles, 208 
depending on the site, environment and other factors. 209 
Binding and transferring the virus is only one part of the story, however.  Most of the HIV-1 210 
susceptible cells in mucosal surfaces are present at lower levels than the top of the epithelium.  211 
Thus, to be a truly effective source of viral transmission, it is necessary for the virus to be 212 
transported through the epithelial layer whilst retaining infectivity. Using transwell cultures, we 213 
demonstrated the transcytosis of infectious virus through an oral or vaginal epithelial cell layer, with 214 
successful infection of susceptible cells on the basal side of the monolayer (Kohli et al., 2014).  Other 215 
studies have also shown transcytosis through vaginal epithelial layers (Kinlock et al., 2014, Ferreira et 216 
al., 2015).  Interestingly, these studies indicate that this is an endocytic pathway dependent 217 
mechanism (Kinlock et al., 2014), and that the female hormone medroxyprogesterone acetate 218 
boosts the transit and subsequent infection (Ferreira et al., 2015). A further study has also 219 
implicated anti-HIV-1 antibody-neonatal Fc receptor interactions as also playing an enhancing role in  220 
the transcytosis of HIV across an epithelial cell surface (Gupta et al., 2013).  This strongly suggests 221 
that host factors are critical in regulating the transport of HIV virions across epithelial surfaces 222 
deeper into the layer and thus subsequent infection of susceptible cells in these tissues.  More, HIV-223 
1 is able to hijack host mechanisms to boost this event.  Investigations using in vivo models suggest 224 
that HIV can indeed successfully pass through the epithelial layer to permissive cells, although much 225 
of this work has been carried out looking at vaginal/genitourinary mucosa (Ferreira et al., 2015:Spira, 226 
1996 #1936, Hu et al., 2000, Baba et al., 1996, Herz et al., 2002, Joag et al., 1997, Milush et al., 227 
2004).  228 
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The data obtained from all these studies lead us to develop the hypothesis that the epithelial cells at 229 
oral and other mucosal surfaces not only bind cell free HIV, but that they also transport infectious 230 
virions deeper into the mucosal layers where they can infect susceptible cells.  231 
Further considerations 232 
It is clearly apparent that different conditions/environments at mucosal surfaces can materially 233 
affect the movement and maintenance of HIV-1 virions within the mucosae.  What we have seen 234 
here is that there are differences in the transmission rates of epithelial surfaces depending on the 235 
status of the epithelial cells or production of host factors. This then leads us to wonder whether the 236 
transmission of virus through the oral epithelium varies with the age of the host.  This is of particular 237 
interest, given the rate of transmission from mother to child.  This mother to child transmission 238 
(MTCT) can occur during pregnancy, labour and delivery or through breast feeding after birth 239 
(Politch et al., 2014). MTCT during pregnancy and labour/delivery occurs in 15-25% of cases unless 240 
specific interventions are made, but a further 5-20%  of infants will be infected as a result of post-241 
natal breast feeding (Politch et al., 2014, Roskoski, 2014). Given the low incidence of transmission 242 
traditionally associated with oral sex (Smith et al., 2005), this suggests that there may be something 243 
different about neonatal/foetal oral epithelium that allows a significant number of infectious events 244 
due to transmission across the oral mucosa. Two recent studies from Tugizov et al suggest that this 245 
might be the case (Tugizov et al., 2011, Tugizov et al., 2012).  In these studies, the authors 246 
determined that there was a significant number in the amount of HIV virions that successfully 247 
traversed the oral epithelium and infected the underlying susceptible cells in fetal/neonatal  oral 248 
epithelium. In contrast, transmission through adult epithelium was reduced.  Further, HIV-1 virions 249 
transcytosed through adult oral epithelium showed reduced infectivity, whereas those transcytosed 250 
through foetal/neonatal epithelium (Tugizov et al., 2011).  The likelihood is that this reduction is due 251 
to an increase in the secretion of anti-HIV factors such as β-defensins 2 and 3, as well as secretory 252 
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leukocyte protease inhibitor (Tugizov et al., 2011).  Thus the age of the host is also a key factor in the 253 
transmission of HIV virions across the epithelial surfaces. 254 
Summary 255 
As we have seen throughout this review, the oral epithelium and the epithelial cells that comprise 256 
the majority of these surfaces are not simply a passive barrier during HIV-1 infections.  In contrast, 257 
they have a significant role to play in infection events as well as potentially acting as reservoirs for 258 
infection. We propose that under normal conditions HIV-1 will bind to adult epithelial cells in the 259 
oral epithelium, but that this binding will not result in productive infection.  However, post-capture, 260 
some of these virus particles may be retained and translocated through the epithelial layer to 261 
underlying target cells which can then be productively infected, although a large percentage of these 262 
virions may be killed or inactivated by host factors. In neonates, however, these host factors play a 263 
far more minor role, meaning that transmission across oral epithelium via epithelial cells and 264 
subsequent infection of susceptible cells is a far more common event.  Thus, further targeting 265 
epithelial cells and the epithelium in general, particularly in neonates and infants represents a highly 266 
viable preventative therapy to halt the spread of HIV infection. 267 
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